公开(公告)号：US20200270335A1

公开(公告)日：2020-08-27

申请号：US16063423

申请日：2016-12-16

Applicant: Biogen MA Inc.

Inventor： R. Blake Pepinsky ,  Richelle Sopko ,  Joshua Mugford ,  Andreas Lehmann ,  Joseph W. Arndt ,  Nels E. Pederson ,  Brenda K. Minesinger

IPC: C07K16/18 ,  A61K47/65 ,  C07K14/765

Abstract: Proteins containing a DKK2 polypeptide or a fragment or variant thereof are described. These proteins contain human serum albumin sequences and/or include substitutions in the DKK2 polypeptide that decrease heparin binding. These proteins are useful in the treatment of disorders such as acute kidney injury and fibrosis.

公开(公告)号：US20160137739A1

公开(公告)日：2016-05-19

申请号：US14891491

申请日：2014-05-30

Applicant: BIOGEN MA INC.

Inventor： Heather A. Arnett ,  Sabine S. Escobar ,  Chadwick T. King ,  Ai Ching Lim ,  Saravanakumar Narayanan ,  Paul H. Weinreb ,  Nels E. Pederson

IPC: C07K16/28

CPC classification number: C07K16/2866 ,  A61K39/395 ,  C07K16/244 ,  C07K16/248 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention provides anti-oncostatin M receptor-β (OSMR) antigen binding proteins. e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.

Abstract translation: 本发明提供抗制霉素M受体 - （OSMR）抗原结合蛋白。 例如抗体和功能片段，衍生物，突变蛋白及其变体。 OSMR抗原结合蛋白干扰OSM和/或IL-31与OSMR的结合。 在一些实施方案中，抗OSMR抗原结合蛋白是研究与OSMR相关的疾病和病症的有用工具，并且特别可用于治疗与OSMR和OSM和/或IL-31与OSMR结合的疾病和病症的方法。

公开(公告)号：US20220089704A1

公开(公告)日：2022-03-24

申请号：US17288445

申请日：2019-10-28

Applicant: Biogen MA Inc. ,  National Research Council of Canada

Inventor： Benjamin A. Smith ,  Andreas Lehmann ,  Thomas O. Cameron ,  R. Blake Pepinsky ,  Dingyi Wen ,  Graham K. Farrington ,  Gopalan Raghunathan ,  Nels E. Pederson ,  Danica Stanimirovic ,  Traian Sulea ,  Arsalan S. Haqqani

IPC: C07K16/18 ,  A61P25/28 ,  C07K16/28 ,  C07K14/47

Abstract: Featured are compositions comprising humanized and engineered variants of an antibody variable domain (e.g., FC5), chimeric molecules comprising same, compositions comprising same, and uses thereof.